Sidoti Csr Has Optimistic Outlook of Balchem Q1 Earnings

Balchem Co. (NASDAQ:BCPC) – Sidoti Csr boosted their Q1 2025 EPS estimates for shares of Balchem in a research report issued to clients and investors on Monday, October 28th. Sidoti Csr analyst K. May now anticipates that the basic materials company will post earnings per share of $1.19 for the quarter, up from their previous estimate of $1.16. The consensus estimate for Balchem’s current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2025 earnings at $1.21 EPS, Q3 2025 earnings at $1.22 EPS, FY2025 earnings at $4.82 EPS and Q1 2026 earnings at $1.27 EPS.

Several other analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a research report on Monday. HC Wainwright lifted their target price on shares of Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st.

Balchem Stock Performance

Balchem stock opened at $167.33 on Wednesday. The firm’s fifty day moving average price is $171.75 and its 200-day moving average price is $162.75. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The stock has a market cap of $5.43 billion, a P/E ratio of 47.27, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65. Balchem has a fifty-two week low of $114.97 and a fifty-two week high of $186.03.

Hedge Funds Weigh In On Balchem

A number of large investors have recently added to or reduced their stakes in BCPC. Vanguard Group Inc. raised its position in Balchem by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock worth $609,873,000 after purchasing an additional 144,423 shares during the period. Price T Rowe Associates Inc. MD raised its position in Balchem by 32.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 193,146 shares of the basic materials company’s stock worth $29,929,000 after purchasing an additional 47,036 shares during the period. Congress Asset Management Co. raised its position in Balchem by 12.4% in the 3rd quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock worth $53,053,000 after purchasing an additional 33,373 shares during the period. Conestoga Capital Advisors LLC grew its holdings in Balchem by 2.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,155,209 shares of the basic materials company’s stock worth $177,844,000 after acquiring an additional 29,825 shares during the last quarter. Finally, Watts Gwilliam & Co. LLC bought a new stake in Balchem in the 3rd quarter worth $3,639,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.